Compare Vedolizumab and AntiTNF-α Dose Escalation for Ulcerative Colitis in the ODESSA-UC Study.

Published Date: 07 Dec 2023

The patients treated with vedolizumab had a lower incidence of dose escalation and a lower chance of needing it than the patients treated with infliximab and adalimumab, according to the results.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot